title: Proteases and antiproteases related to the coagulation system in plasma and ascites--influence of dexamethasone.
abstract: Fibrinolysis induced by the infusion of plasminogen activators into the circulation has been shown to cause coagulation disorders in ascites retransfusion. Dexamethasone is known to inhibit the synthesis of plasminogen activators by peritoneal macrophages. We therefore assessed its potential in preventing the occurrence of fibrinolysis by injecting 16 mg dexamethasone intraperitoneally in 10 patients 24 h before ascites retransfusion was performed. In addition, the effect of dexamethasone upon the activity or concentration of several proteases and antiproteases related to coagulation in plasma and ascites was analyzed on 15 occasions. An increase of the activity of plasminogen, alpha 2-antiplasmin, and antithrombin III, and in the concentration of alpha 1-protease inhibitor in ascites was induced by the dexamethasone injection. However, the reaction was not identical in all patients. Those patients having an increase of plasminogen activities of 0.6 CTA U/ml or more did not show signs of fibrinolysis during retransfusion. The results obtained indicate that intraperitoneal injection of dexamethasone decreases the concentration of plasminogen activators in ascites and thereby reduces the risk of coagulation disorders during retransfusion procedures. Since the effect is variable and not sustained, assessment of preoperative plasminogen concentrations is mandatory in order to prevent complications.
authors.forename: J
authors.initials: J
authors.lastname: Schölmerich
authors.forename: U
authors.initials: U
authors.lastname: Zimmermann
authors.forename: E
authors.initials: E
authors.lastname: Köttgen
authors.forename: B A
authors.initials: BA
authors.lastname: Volk
authors.forename: C
authors.initials: C
authors.lastname: Hasler
authors.forename: W
authors.initials: W
authors.lastname: Diener
authors.forename: W
authors.initials: W
authors.lastname: Gerok
mesh_terms: D000990:Antithrombin III / Q000378:metabolism; D001201:Ascites / Q000188:drug therapy* / Q000201:enzymology; D001779:Blood Coagulation Factors / Q000378:metabolism*; D001780:Blood Coagulation Tests; D003907:Dexamethasone / Q000627:therapeutic use*; D005260:Female; D005338:Fibrin Fibrinogen Degradation Products / Q000378:metabolism; D006801:Humans; D008297:Male; D010447:Peptide Hydrolases / Q000097:blood*; D010536:Peritoneovenous Shunt; D010958:Plasminogen / Q000378:metabolism; D011480:Protease Inhibitors / Q000097:blood*; D000979:alpha-2-Antiplasmin / Q000378:metabolism
chemical_list: D001779:Blood Coagulation Factors; D005338:Fibrin Fibrinogen Degradation Products; D011480:Protease Inhibitors; D000979:alpha-2-Antiplasmin; D003907:Dexamethasone; D000990:Antithrombin III; D010958:Plasminogen; D010447:Peptide Hydrolases